Showing 3851-3860 of 4165 results for "".
- Sight Sciences OMNI Surgical System to Be Featured in Multiple Presentations at the 2022 ESCRShttps://modernod.com/news/sight-sciences-omni-surgical-system-to-be-featured-in-multiple-presentations-at-the-2022-escrs/2481099/Sight Sciences announced that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European Society of Cataract & Refractive Surgeons (ESCRS) meeting in Milan, Italy from September 16-20. At Sight Sciences Booth A2
- Oculis Announces Publication and Presentation of Phase 2 Data Showing Topical OCS-01 Improves Macular Thickness and Visual Acuity in Patients with DMEhttps://modernod.com/news/oculis-announces-publication-and-presentation-of-phase-2-data-showing-topical-ocs-01-improves-macular-thickness-and-visual-acuity-in-patients-with-dme/2481066/Oculis SA announced that the phase 2 DX-211, a randomized, double blinded, multicenter and vehicle controlled clinical trial assessing the safety and efficacy of topical OCS-01 in patients with diabetic macular edema (DME) (NCT05343156) has been published in the journal Acta Ophthalmolog
- Vyluma Completes Last Patient Visit for Phase 3 CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-completes-last-patient-visit-for-primary-analysis-of-pivotol-phase-iii-champ-study-evaluating-nvk002-for-the-treatment-of-myopia-progression-in-children/2481059/Vyluma announced that the last patient visit has been completed for the primary analysis of the pivotal phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. The CHAMP study has been designed, in collaboration with the FDA, to evaluate whether NVK002 eye drops are safe and eff
- Isarna Therapeutics Presents Update From Phase 2 BETTER Study in Wet AMD and DME at the EURETINA Meetinghttps://modernod.com/news/isarna-therapeutics-presents-update-from-phase-2-better-clinical-study-in-wet-amd-and-dme-at-the-euretina-meeting/2481056/Isarna Therapeutics presented an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Marion Munk, MD, PhD, FEBO, and the CMO of Isarna Therapeutics provided initial positive safety results and effic
- Alimera Announces Multiple Abstracts Highlighting ILUVIEN Real-World Data at EURETINA Annual Congresshttps://modernod.com/news/alimera-announces-multiple-abstracts-highlighting-iluvien-real-world-data-at-euretina-annual-congress/2481055/Alimera Sciences announced that clinical data for ILUVIEN (fluocinolone acetonide intravitreal implant 0.19mg) will be featured in more than 20 scientific abstracts during the EURETINA 2022 congress being held in Hamburg, Germany from September 1-4, 2022. Audio Na
- Oculis Announces Publication of Phase 2 Data Showing Eye Drop Drug Candidate Relieves Persistent Ocular Discomfort in Severe Dry Eye Diseasehttps://modernod.com/news/oculis-announces-publication-of-phase-2-data-showing-topical-eye-drop-drug-candidate-ocs-02-relieves-persistent-ocular-discomfort-in-severe-dry-eye-disease/2481042/Oculis announced that the results of the double blinded, multicenter and placebo controlled phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort in patients with severe dry eye disease (DED) has been published by the journal C
- Research to Prevent Blindness and the American Academy of Ophthalmology Award New Research Grants to Improve Eye Carehttps://modernod.com/news/research-to-prevent-blindness-and-the-american-academy-of-ophthalmology-award-new-research-grants-to-improve-eye-care/2481025/The American Academy of Ophthalmology and Research to Prevent Blindness (RPB) announced the 2022 recipients of the RPB/AAO Award for IRIS Registry Research. The researchers will use the IRIS Registry—the nation’s first and largest comprehensive eye disease clinical registry—to c
- Clearside Biomedical Enters Into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for Up to $65 Millionhttps://modernod.com/news/clearside-biomedical-enters-into-non-dilutive-financing-agreement-with-healthcare-royalty-partners-for-up-to-65-million/2481020/Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million. Clearside intends to use the proceeds from the agreement to support ongoing clinical development of its pipeline, including CLS-AX (axitini
- Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Diseasehttps://modernod.com/news/tarsus-initiates-phase-2a-ersa-trial-evaluating-tp-03-for-the-treatment-of-meibomian-gland-disease/2481015/Tarsus Pharmaceuticals announced that it has enrolled the first patient in a phase 2a clinical trial studying TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of meibomian gland disease (MGD) in patients with Demodex mites. Demodex
- Yuyu Pharma Announces First Patient Enrolled in Phase 2 Study of YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Diseasehttps://modernod.com/news/yuyu-pharma-announces-first-patient-enrolled-in-phase-2-clinical-study-evaluating-yp-p10-ophthalmic-solution-for-the-treatment-of-dry-eye-disease/2480996/Yuyu Pharma announced the enrollment of the first patient in a phase 2 clinical study evaluating YP-P10, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties being investigated to treat patients with dry eye disease (DED). Yuyu received cl